Detalhe da pesquisa
1.
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Int J Infect Dis;
122: 585-592, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35788416